Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 16/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.53 |
| ▸ | RPTOR | Q8N122 | 8/20 | 0.50 |
| ▸ | MLST8 | Q9BVC4 | 8/20 | 0.50 |
| ▸ | RICTOR | Q6R327 | 2/20 | 0.50 |
| ▸ | MAPKAP1 | Q9BPZ7 | 2/20 | 0.50 |
| ▸ | CSF1R | P07333 | 1/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29522121 | 0.79 | MTOR (0.63) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL138866 | 0.79 | MTOR (0.63) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL138861 | 0.79 | MTOR (0.62) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL29522551 | 0.79 | MTOR (0.62) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL137259 | 0.74 | MTOR (0.76) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL29522486 | 0.74 | MTOR (0.76) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL138370 | 0.72 | MTOR (0.77) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL29522252 | 0.72 | MTOR (0.77) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL29522050 | 0.71 | MTOR (0.74) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL137235 | 0.71 | MTOR (0.74) | MTORPIK3CARPTORMLST8RICTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3313403-A1 | TREATMENT OF CANCER WITH DNAPK INHIBITORS | Celgene Corporation (US) | 2018-05-02 | — | — | EP | claimed |
| WO-2016210046-A1 | TREATMENT OF CANCER WITH DNAPK INHIBITORS | CELGENE CORPORATION (US) | 2016-12-29 | — | — | WO | claimed |
| EP-2598885-A1 | BIOMARKER ASSAYS FOR DETECTING OR MEASURING INHIBITION OF TOR KINASE ACTIVITY | Signal Pharmaceuticals, LLC (US) | 2013-06-05 | — | — | EP | claimed |
| EP-2493472-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | Signal Pharmaceuticals, LLC (US) | 2012-09-05 | — | — | EP | claimed |
| WO-2012016113-A1 | BIOMARKER ASSAYS FOR DETECTING OR MEASURING INHIBITION OF TOR KINASE ACTIVITY | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-02-02 | — | — | WO | claimed |
| WO-2011053518-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-05-05 | — | — | WO | claimed |
| EP-3313403-A1 | TREATMENT OF CANCER WITH DNAPK INHIBITORS | Celgene Corporation (US) | 2018-05-02 | — | — | EP | disclosed |
| EP-3131552-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | Signal Pharmaceuticals, LLC (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-3131550-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | Signal Pharmaceuticals, LLC (US) | 2017-02-22 | — | — | EP | disclosed |
| WO-2016210046-A1 | TREATMENT OF CANCER WITH DNAPK INHIBITORS | CELGENE CORPORATION (US) | 2016-12-29 | — | — | WO | disclosed |
| EP-3052093-A1 | A TOR KINASE INHIBITOR IN THE PREVENTION OR TREATMENT OF CANCER CHARACTERIZED BY GENE MUTATIONS | Signal Pharmaceuticals, LLC (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-2986298-A1 | TREATMENT OF CANCER WITH DIHYDROPYRAZINO-PYRAZINES | Signal Pharmaceuticals, LLC (US) | 2016-02-24 | — | — | EP | disclosed |
| EP-2986299-A1 | TREATMENT OF CANCER WITH DIHYDROPYRAZINO-PYRAZINES | Signal Pharmaceuticals, LLC (US) | 2016-02-24 | — | — | EP | disclosed |
| WO-2014066125-A2 | INHIBITION OF PHOSPHORYLATION OF PRAS40, GSK3-BETA OR P70S6K1 AS A MARKER FOR TOR KINASE INHIBITORY ACTIVITY | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-05-01 | — | — | WO | disclosed |
| WO-2014062878-A2 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-04-24 | — | — | WO | disclosed |
| WO-2013019927-A1 | IDENTIFICATION OF GENE EXPRESSION PROFILE AS A PREDICTIVE BIOMARKER FOR LKB1 STATUS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-02-07 | — | — | WO | disclosed |
| EP-2531194-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2012-12-12 | — | — | EP | disclosed |
| EP-2493472-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | Signal Pharmaceuticals, LLC (US) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011097333-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011053518-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-05-05 | — | — | WO | disclosed |